Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2021-09-14 Interim / Quarterly Rep…
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about top-line data from a clinical study and financial highlights for the second quarter ended June 30, 2021, including condensed consolidated interim financial statements. Form 6-K is used for submitting current reports by foreign private issuers and typically contains interim financial information and other material events. The document length is 2626 characters, which is relatively short and includes financial highlights and interim financial statements, indicating it is an interim or quarterly report rather than just an announcement or press release. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2021-09-14 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a clinical study and financial highlights for the second quarter ended June 30, 2021, including condensed consolidated interim financial statements. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F. The presence of interim financial statements and financial highlights indicates this is an interim or quarterly report. The document length is 2680 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2021-09-13 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, RedHill Biopharma Ltd. It includes a press release and financial highlights for the second quarter ended June 30, 2021, with condensed consolidated interim financial statements. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F. The presence of interim financial statements and financial highlights indicates this is an interim or quarterly report. The document length is 2586 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2021-09-07 English
6-K
Interim / Quarterly Report Classification · 90% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about new analyses presented at a conference and financial highlights for the second quarter ended June 30, 2021, including condensed interim financial statements. The document length is 2584 characters, which is relatively short and includes references to exhibits and incorporation by reference into registration statements. The document does not contain full detailed financial statements or comprehensive analysis itself but rather serves as a report of interim financial highlights and a press release. Form 6-K filings are typically used by foreign private issuers to report material information and interim financial data between annual reports. Given the nature of the content (interim financial highlights and condensed financial statements) and the form type (6-K), the best classification is Interim / Quarterly Report (IR).
2021-09-07 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about upcoming presentations and financial highlights for the second quarter ended June 30, 2021, along with condensed interim financial statements. Form 6-K is used by foreign private issuers to report material information between annual reports. The presence of condensed interim financial statements and financial highlights indicates this is an interim or quarterly report. The document length is 2641 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2021-09-02 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to the Securities Exchange Act of 1934. It includes a press release reporting second quarter 2021 financial results and operational highlights, as well as condensed consolidated interim unaudited financial information for the three and six months ended June 30, 2021. The presence of interim unaudited financial statements and operational highlights for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is 2676 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, it should be classified as an Interim / Quarterly Report (IR).
2021-08-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.